mRNA cancer vaccines showed promising pancreatic cancer trial results and boosted tumor-fighting drugs in other research. U.S. officials canceled $500 million in vaccine funding, while the NCI is backing a $200 million cancer vaccine partnership.
The global GMP consumables market is projected for significant growth through 2035, driven by expansion in biologics, cell and gene therapies, and mRNA vaccine manufacturing. The market will shift from basic contamination control to enabling advanced therapeutic production with specialized single-use systems. Growth will be supported by regulatory standards, supply chain resilience, and increasing biosimilar production in Asia-Pacific and emerging markets.
Federal vaccine advisers have dropped a plan to reconsider mRNA COVID-19 vaccine recommendations amid Republican concerns about midterm election impacts. The committee maintains its September 2025 decision on shared clinical decision-making.
New market reports forecast significant expansion in CAR T-cell therapy, US pharmaceutical drug delivery, and healthcare nanotechnology sectors, driven by chronic disease prevalence and technological advances.
Researchers have created a nasal vaccine platform that protects mice against flu, COVID-19, SARS, and bacterial infections by activating both innate and adaptive immune systems, offering a fundamentally different approach to disease prevention.
Sixteen pharmaceutical companies have voluntarily agreed to Most Favored Nation pricing covering 70% of Medicare drug spending, while industry leaders warn of China's growing competitiveness in drug development and clinical trials.
The pharmaceutical industry is experiencing recovery driven by innovation in drug development, aggressive M&A activity, and expansion of drug development services. The sector faces both opportunities and headwinds including pipeline setbacks and regulatory pressures.
Researchers developed a post-assembly crosslinking approach that improves the structural stability and endosomal escape efficiency of mRNA lipid nanoparticles, potentially expanding applications for RNA therapeutics and vaccines.
Moderna's seasonal influenza vaccine candidate mRNA-1010 receives FDA acceptance after initial refusal, with a PDUFA date set for August 5, 2026. The revised application proposes full approval for adults 50-64 and accelerated approval for those 65 and older.
Moderna partners with Recordati on propionic acidemia therapy for up to $160 million, while FDA Commissioner defends mRNA vaccine support following funding cuts and regulatory challenges.
